Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Chemoproteomics company uncloaks with $130 million
by Shi En Kim
January 12, 2023
| A version of this story appeared in
Volume 101, Issue 2
Belharra Therapeutics has emerged from stealth with $50 million in series A funding from Versant Ventures and an $80 million multiyear collaboration deal with Genentech. With a founding team that includes Benjamin Cravatt of Scripps Research in California and Stuart Schreiber of the Broad Institute of MIT and Harvard, Belharra aims to screen for noncovalent small-molecule drugs with its chemical probe technology, which the company touts as working for any protein binding site in any cell type.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter